Justin Keywood
Justin Keywood is an analyst at Stifel who covers HLS Therapeutics Inc. He recently adjusted his target for the company while maintaining a hold rating, noting the challenges in meeting growth targets and the potential impact of share buybacks on stock performance amid limited liquidity.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| Canada | 1 | 5.00 | 0.04% | +0% | 38,005,238 | 16,676 | $1,700,000 | 746$ |
| Totals | 1 | 38,005,238 | 16,676 | $1,700,000 | 746$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Canada:
Stifel’s Justin Keywood bumped his Street-low HLS Therapeutics Inc. target to $4 with a 'hold' rating.
5